NCT00796562View on ClinicalTrials.gov

Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

June 30, 2014

Study Completion Date

November 30, 2016

Conditions
MDSLeukemiasLymphomas
Interventions
DRUG

Busulfan

Participant will receive Busulfan injections, 4 times a day for 4 days with dilantin prophylaxis (in patients 10 years of age or older). Busulfan levels in the blood will be measured and dose adjusted, if needed.

DRUG

Cyclophosphamide

Patient will receive Cy by IV once a day for 2 days.

RADIATION

Total body irradiation

Patients will receive TBI once a day for 4 days.

Trial Locations (2)

21231

Sidney Kimmel Comprehensive Cancer Center, Baltimore

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

Sponsors
All Listed Sponsors
collaborator

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY

collaborator

National Center for Research Resources (NCRR)

NIH

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT00796562 - Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy | Biotech Hunter | Biotech Hunter